Life Sciences

  • February 26, 2026

    Feds Back Pharma In 340B Contract Pharmacy Disputes

    State laws that block drugmakers from imposing restrictions on federally funded hospitals and the contract pharmacies they use to dispense discounted drugs under the 340B drug discount program are violating federal law, the Trump administration said, siding with manufacturers in their bid to strike down these laws.

  • February 25, 2026

    Online Abortion Pill Provider Illegally Ships To Texas, AG Says

    Texas Attorney General Ken Paxton sued Aid Access, its founder and a California doctor in state court Tuesday alleging they operate an "abortion-by-mail enterprise" that ship abortion-inducing drugs to Texas residents, which is endangering the lives of unborn children and their mothers. 

  • February 25, 2026

    White House Cites Fraud, Freezes $259M In Minn. Medicaid

    The Trump administration on Wednesday said it would hold back $259.9 million in Medicaid funding for Minnesota as part of what it called an unprecedented effort to combat fraud in programs that support low-income families.

  • February 25, 2026

    Fed. Circ. Gene Therapy Ruling Gives Rare Eligibility Clarity

    When the Federal Circuit revived the University of Pennsylvania's gene therapy patent last week, it provided a bright-line rule that's often missing in the debate over patent eligibility, attorneys say.

  • February 25, 2026

    $17.9M Drug Price-Fixing Deal Advances Despite Objections

    A Connecticut federal judge on Wednesday advanced a $17.9 million generic drug price-fixing settlement between 48 states and territories and pharmaceutical companies Bausch Health US LLC, Bausch Health Americas Inc. and Lannett Co. Inc., sidelining objections by consumers suing separately in a Pennsylvania multidistrict litigation case.

  • February 25, 2026

    Birth Control Shot Plaintiffs Lose Mid-Case Appeal Bid In Del.

    The Delaware Supreme Court has refused to hear an interlocutory appeal in product liability litigation over the contraceptive injection Depo-Provera, leaving in place a set of case-management orders designed to streamline what is expected to become hundreds of lawsuits in the state.

  • February 25, 2026

    NJ Judge Trims J&J And Neutrogena Benzene Suit

    A New Jersey federal judge has slashed state and common law claims in a multistate proposed class action alleging that acne cream produced by Johnson & Johnson Consumer Inc. and Kenvue Inc. contained a cancer-causing chemical without warning labels, saying the buyers' claims missed "a step" and were "circular."

  • February 25, 2026

    9th Circ. Undoes $278M Eli Lilly Payment In Insulin Case

    The Ninth Circuit ruled against a lower court Wednesday in saying pharmaceutical giant Eli Lilly does not owe $278 million in royalties to an Arizona company for insulin-brands sales, saying an agreement between the companies did not cover insulin products Eli Lilly made using a certain yeast expression technology.

  • February 25, 2026

    Philly Says PBMs Can't Exit Suit Over Opioid Crisis

    The city of Philadelphia on Wednesday defended its lawsuit against CVS Health Corp. and other pharmacy benefit managers over allegedly fueling the opioid crisis, urging a Pennsylvania federal judge to reject the PBMs' arguments that they should be let out of the litigation for lack of a valid legal claim.

  • February 25, 2026

    Hagens Berman Fights Fee Demand Amid Misconduct Claims

    Hagens Berman Sobol Shapiro LLP has blasted as premature a bid from drugmakers in Pennsylvania federal court calling for the firm to cover the fees and costs of a special master who alleged the firm committed misconduct in product liability actions over the morning sickness drug thalidomide.

  • February 25, 2026

    Life Sciences Group Of The Year: Davis Polk

    Davis Polk & Wardwell LLP attorneys advised Intra-Cellular Therapies Inc. on its $14.6 billion sale to Johnson & Johnson, guided Endo Inc. through its $6.7 billion merger with Mallinckrodt PLC and advised Novo Nordisk in its proposed $9.1 billion acquisition of Metsera, earning it a spot among the 2025 Law360 Life Sciences Groups of the Year. 

  • February 25, 2026

    Taft Adds 5-Person IP Team From McAndrews Held

    Taft Stettinius & Hollister LLP announced on Wednesday that it has hired a group of four attorneys and one patent agent from McAndrews Held & Malloy Ltd. in the Chicago, Minneapolis and West Palm Beach, Florida, offices.

  • February 25, 2026

    Budtender Alleges Dispensary Gives Tips To Managers

    A proposed class of budtenders is suing an Illinois dispensary and its management company, saying they violate state and federal labor law by pooling tips and distributing them to managers as well as the budtenders.

  • February 25, 2026

    Moderna's Damages Expert Limited In March Patent Trial

    Moderna's damages expert was blocked from offering testimony about what a reasonable royalty would be in a suit alleging its COVID-19 vaccine infringed a rival's patents, after a federal judge found that part of the testimony wasn't reliable.

  • February 25, 2026

    Novo's $2.1B Vivtex Deal Boosts Obesity Drug Pipeline

    Novo Nordisk said on Wednesday it is partnering with Vivtex Corp. on a deal worth up to $2.1 billion to develop drugs for obesity and related conditions, pressing ahead with a weight loss-drug franchise that has delivered rapid growth alongside regulatory scrutiny and courtroom clashes.

  • February 24, 2026

    9th Circ. Grants Atty Fee Appeal In Eye Drop Pricing Suit

    District courts cannot reduce fee awards to attorneys based on a firm's size, the Ninth Circuit ruled in a published opinion Tuesday, sending a case back to a California federal court to recalculate attorney fees awarded to a "small" firm that represented wholesalers in a Robinson-Patman Act suit against eye drop manufacturers.

  • February 24, 2026

    Ariz., Calif. Lead Suit Over 'Senseless' HHS Vaccine Overhaul

    Arizona and California are leading a coalition of states challenging the U.S. Department of Health and Human Services' decision to cut vaccine recommendations for American children, alleging in a lawsuit Tuesday that the "unprecedented attack" stems from HHS Secretary Robert F. Kennedy Jr.'s "unscientific hostility to vaccines."

  • February 24, 2026

    Ex-Med School Dean Claims Fla. College Broke Work Contract

    The former dean of Florida International University's medical school told a state court that the university breached his employment contract by refusing to pay him the salary promised in their agreement and undermined his independence.

  • February 24, 2026

    Judge Says 'Error' Kept Mallinckrodt Execs In Investor Suit

    Two former Mallinckrodt executives have escaped the only remaining claims they faced in an investor suit tied to the company's 2023 bankruptcy and share cancellations after a New Jersey federal judge said he made a "clear error" keeping them in the suit last year.

  • February 24, 2026

    6th Circ. Affirms Dismissal Of Sotera Toxic Gas Investor Suit

    The Sixth Circuit on Tuesday affirmed a lower court's dismissal of an investor lawsuit accusing Sotera Health Co. of concealing the carcinogenic nature of a gas used at its sterilization plants, finding Sotera did not make any actionable false or misleading statements to investors.

  • February 24, 2026

    Lindis Decries Erasing $50M Verdict Over Inequitable Conduct

    A Delaware federal judge wrongly overruled Lindis Biotech's $50 million infringement verdict against Amgen by falsely concluding an inventor intended to deceive the patent office during prosecution, the German company has told the Federal Circuit.

  • February 24, 2026

    High Court Won't Stay Dow Corning Breast Implant Fund Row

    The U.S. Supreme Court on Tuesday denied a request to stay a lower court's order permanently wiping out the claims of more than 2,600 Koreans who said they were failed by how the settlement was structured, as they were given notice only in English regarding their claims.

  • February 24, 2026

    Novo Nordisk Wants Expert Cut From Hospital Insulin Pen Suit

    Novo Nordisk on Tuesday asked a Connecticut federal judge to remove an expert witness's report and related testimony from an insulin pen contamination lawsuit, hoping a hospital's entire case fails once the expert's opinions are blocked.

  • February 24, 2026

    Mallinckrodt's Ch. 11 Blocks Antitrust Payouts, Judge Rules

    A Connecticut federal judge has ruled that drugmaker Mallinckrodt PLC shrugged off monetary claims brought by states in a sprawling generic drug antitrust enforcement action when the company emerged from bankruptcy in 2022.

  • February 24, 2026

    Philips Unit Escapes CPAP Machine Whistleblower Case

    Philips Respironics, a unit of Koninklijke Philips NV, fended off a whistleblower suit alleging it provided kickbacks to CPAP suppliers that bought its products, with a Pennsylvania federal judge ruling that a former Philips manager failed to show that the company willfully engaged in illegal conduct.

Expert Analysis

  • Series

    My Miniature Livestock Farm Makes Me A Better Lawyer

    Author Photo

    Raising miniature livestock on my farm, where I am fully present with the animals, is an almost meditative time that allows me to return to work invigorated, ready to juggle numerous responsibilities and motivated to tackle hard issues in new ways, says Ted Kobus at BakerHostetler.

  • Surveying The Healthcare Policy Landscape Post-Shutdown

    Author Photo

    With last week's agreement to reopen the federal government, at least through the end of January, key healthcare legislation that has been in limbo since a December 2024 spending bill fell apart may recapture the attention of Congress, say attorneys at Faegre Drinker.

  • FDA Biosimilar Guidance Should Ease Biologics Development

    Author Photo

    New draft guidance from the U.S. Food and Drug Administration, indicating that the agency may no longer routinely require comparative efficacy studies when other evidence provides sufficient assurance of biosimilarity, underscores the FDA's trust in analytical technology as a driver of biologics access, say attorneys at Hogan Lovells.

  • Litigation Funding Could Create Ethics Issues For Attorneys

    Author Photo

    A litigation investor’s recent complaint claiming a New York mass torts lawyer effectively ran a Ponzi scheme illustrates how litigation funding arrangements can subject attorneys to legal ethics dilemmas and potential liability, so engagement letters must have very clear terms, says Matthew Feinberg at Goldberg Segalla.

  • E-Discovery Quarterly: Recent Rulings On Dynamic Databases

    Author Photo

    Several recent federal court decisions illustrate how parties continue to grapple with the discovery of data in dynamic databases, so counsel involved in these disputes must consider how structured data should be produced consistent with the requirements of the Federal Rules of Civil Procedure, say attorneys at Sidley.

  • How Litigating Antitrust Fix Helped GTCR Prevail In Court

    Author Photo

    An Illinois federal judge's recent denial of the Federal Trade Commission's injunction request in the GTCR acquisition of Surmodics joins a developing series of cases in which deal parties have prevailed against government antitrust challenges by proposing a post-complaint fix and litigating the as-amended deal, say attorneys at Paul Weiss.

  • Series

    Building With Lego Makes Me A Better Lawyer

    Author Photo

    Building with Lego has taught me to follow directions and adapt to unexpected challenges, and in pairing discipline with imagination, allows me to stay grounded while finding new ways to make complex deals come together, says Paul Levin at Venable.

  • The Rise Of Trade Secret Specificity As A Jury Question

    Author Photo

    Recent federal appellate court decisions have clarified that determining sufficient particularity under the Defend Trade Secrets Act is a question of fact and will likely become a standard jury question, highlighting the need for appropriate jury instructions that explicitly address the issue, says Amy Candido at Simpson Thacher.

  • Series

    Law School's Missed Lessons: Networking 101

    Author Photo

    Cultivating a network isn't part of the law school curriculum, but learning the soft skills needed to do so may be the key to establishing a solid professional reputation, nurturing client relationships and building business, says Sharon Crane at Practising Law Institute.

  • Defeating Estoppel-Based Claims In Legal Malpractice Actions

    Author Photo

    State supreme court cases from recent years have addressed whether positions taken by attorneys in an underlying lawsuit can be used against them in a subsequent legal malpractice action, providing a foundation to defeat ex-clients’ estoppel claims, says Christopher Blazejewski at Sherin and Lodgen.

  • Trade Secret Rulings Reveal The Cost Of Poor Preparation

    Author Photo

    Two recent federal appellate decisions show that companies must be prepared to prove their trade secrets with specificity, highlighting how an asset management program that identifies key confidential information before litigation arises can provide the clarity and documentation that courts increasingly require, say attorneys at Mintz.

  • Series

    The Biz Court Digest: How It Works In Massachusetts

    Author Photo

    Since its founding in 2000, the Massachusetts Business Litigation Session's expertise, procedural flexibility and litigant-friendly case management practices have contributed to the development of a robust body of commercial jurisprudence, say James Donnelly at Mirick O’Connell, Felicia Ellsworth at WilmerHale and Lisa Wood at Foley Hoag.

  • Why Appellees Should Write Their Answering Brief First

    Author Photo

    Though counterintuitive, appellees should consider writing their answering briefs before they’ve ever seen their opponent’s opening brief, as this practice confers numerous benefits related to argument structure, time pressures and workflow, says Joshua Sohn at the U.S. Department of Justice.

  • Navigating DEA Quotas: Key To Psychedelics Industry Growth

    Author Photo

    As new compounds like DOI enter the Schedule I landscape, manufacturers who anticipate U.S. Drug Enforcement Administration quota regulations, and build quota management into their broader strategy, will be best equipped to meet the growing demand, say Kimberly Chew at Husch Blackwell and Jaime Dwight at Promega.

  • Series

    Mindfulness Meditation Makes Me A Better Lawyer

    Author Photo

    Mindful meditation enables me to drop the ego, and in helping me to keep sight of what’s important, permits me to learn from the other side and become a reliable counselor, says Roy Wyman at Bass Berry.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.